Renal oncocytoma differential diagnosis: Difference between revisions
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) |
||
Line 50: | Line 50: | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Central scar | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Papillary | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | structures | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Classic | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | architectural | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | pattern | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nuclei | |||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CK7 | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |KIT | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vimentin | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |AMACR | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |SDHB | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Melanocytic | |||
markers | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 2 | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 2 | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 3 | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 3 | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oncocytoma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Oncocytoma | ||
| style="background: #F5F5F5; padding: 5px;" |Classic but | |||
only subset | |||
| style="background: #F5F5F5; padding: 5px;" |No or rare | |||
abortive | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |+ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 83: | Line 96: | ||
RCC, eosinophilic | RCC, eosinophilic | ||
| style="background: #F5F5F5; padding: 5px;" |Sometimes | |||
| style="background: #F5F5F5; padding: 5px;" |No | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |+ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 102: | Line 115: | ||
RCC, classic | RCC, classic | ||
| style="background: #F5F5F5; padding: 5px;" |Sometimes | |||
| style="background: #F5F5F5; padding: 5px;" |No | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |+ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 121: | Line 134: | ||
RCC | RCC | ||
| style="background: #F5F5F5; padding: 5px;" |Unknown | |||
| style="background: #F5F5F5; padding: 5px;" |Usually no | |||
(rare variant | |||
cases) | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |- (mast | ||
cells | |||
present) | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 140: | Line 161: | ||
eosinophilic | eosinophilic | ||
| style="background: #F5F5F5; padding: 5px;" |Usually not | |||
| style="background: #F5F5F5; padding: 5px;" |Yes | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |- | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 159: | Line 180: | ||
RCC | RCC | ||
| style="background: #F5F5F5; padding: 5px;" |Usually not | |||
| style="background: #F5F5F5; padding: 5px;" |No | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |- | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 176: | Line 197: | ||
|- | |- | ||
|Epithelioid AML | |Epithelioid AML | ||
|Usually not | |||
|No | |||
| | | | ||
| | |<nowiki>-</nowiki> | ||
| | | | ||
| | | |
Revision as of 12:23, 2 May 2019
Renal oncocytoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Renal oncocytoma differential diagnosis On the Web |
American Roentgen Ray Society Images of Renal oncocytoma differential diagnosis |
Risk calculators and risk factors for Renal oncocytoma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2] Shanshan Cen, M.D. [3]
Overview
Renal oncocytoma must be differentiated from renal cell carcinoma, metanephric neoplasms, and renal leiomyoma.
Differential Diagnosis
Renal oncocytoma must be differentiated from:
- Renal cell carcinoma (RCC)[1]
- Metanephric neoplasms
- Metanephric adenoma
- Metanephric adenofibroma
- Renal leiomyoma
Overview
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
Differentiating [Disease name] from other Diseases
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
[Disease name] must be differentiated from [differential dx1], [differential dx2], and [differential dx3].
OR
As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||
Central scar | Papillary
structures |
Classic
architectural pattern |
Nuclei | CK7 | KIT | Vimentin | AMACR | SDHB | Melanocytic
markers |
Imaging 2 | Imaging 3 | ||||
Oncocytoma | Classic but
only subset |
No or rare
abortive |
+ | ||||||||||||
Chromophobe
RCC, eosinophilic |
Sometimes | No | + | ||||||||||||
Chromophobe
RCC, classic |
Sometimes | No | + | ||||||||||||
SDH-deficient
RCC |
Unknown | Usually no
(rare variant cases) |
- (mast
cells present) |
||||||||||||
Papillary RCC,
eosinophilic |
Usually not | Yes | - | ||||||||||||
Tubulocystic
RCC |
Usually not | No | - | ||||||||||||
Epithelioid AML | Usually not | No | - |
References
- ↑ Renal oncocytoma.Dr Donna D'Souza et al. Radiopaedia.org 2015.http://radiopaedia.org/articles/renal-oncocytoma